{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T12:13:01Z","timestamp":1775909581889,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100013227","name":"Health Promotion Administration, Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["(H25-cancer, clinical-general-006"],"award-info":[{"award-number":["(H25-cancer, clinical-general-006"]}],"id":[{"id":"10.13039\/100013227","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s12185-022-03347-3","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T18:04:38Z","timestamp":1651687478000},"page":"228-238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial"],"prefix":"10.1007","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3683-7147","authenticated-orcid":false,"given":"Yasushi","family":"Miyazaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Kiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Dobashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Handa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Horiike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoshi","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Hata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumihisa","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Iyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Suzushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiyoshi","family":"Moriuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Ohtake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Naoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"On behalf of Japan Adult Leukemia Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3683-7147","authenticated-orcid":false,"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Dobashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Handa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Horiike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoshi","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumihisa","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,4]]},"reference":[{"key":"3347_CR1","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1056\/NEJMra1904794","volume":"383","author":"M Cazzola","year":"2020","unstructured":"Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383:1358\u201374.","journal-title":"N Engl J Med"},{"key":"3347_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223\u201332.","journal-title":"Lancet Oncol"},{"key":"3347_CR3","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1200\/JCO.2008.17.1058","volume":"27","author":"RM Lyons","year":"2009","unstructured":"Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD, Cohn AL, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol. 2009;27:1850\u20136.","journal-title":"J Clin Oncol"},{"key":"3347_CR4","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/ajh.21482","volume":"84","author":"MG Martin","year":"2009","unstructured":"Martin MG, Walgren RA, Procknow E, Uy GL, Stockerl-Goldstein K, Cashen AF, et al. A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes. Am J Hematol. 2009;84:560\u20134.","journal-title":"Am J Hematol"},{"key":"3347_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1182\/blood-2010-06-289280","volume":"117","author":"R Itzykson","year":"2011","unstructured":"Itzykson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117:403\u201311.","journal-title":"Blood"},{"key":"3347_CR6","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.leukres.2014.03.004","volume":"38","author":"R Garc\u00eda-Delgado","year":"2014","unstructured":"Garc\u00eda-Delgado R, De Miguel D, Bailen A, Gonz\u00e1lez JR, Bargay J, Falantes JF, et al. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia. Leuk Res. 2014;38:744\u201350.","journal-title":"Leuk Res"},{"key":"3347_CR7","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3109\/10428194.2014.935366","volume":"56","author":"DL Grinblatt","year":"2015","unstructured":"Grinblatt DL, Sekeres MA, Komrokji RS, Swern AS, Sullivan KA, Narang M. Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA registry. Luek Lymphoma. 2015;56:887\u201395.","journal-title":"Luek Lymphoma"},{"key":"3347_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","volume":"51","author":"JM Bennett","year":"1982","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189\u201399.","journal-title":"Br J Haematol"},{"key":"3347_CR9","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"LR Silverman","year":"2002","unstructured":"Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429\u201340.","journal-title":"J Clin Oncol"},{"key":"3347_CR10","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer (IARC); 2008."},{"key":"3347_CR11","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079\u201388.","journal-title":"Blood"},{"key":"3347_CR12","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sol\u00e9 F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"key":"3347_CR13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419\u201325.","journal-title":"Blood"},{"key":"3347_CR14","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00277-019-03724-9","volume":"98","author":"E Scalzulli","year":"2019","unstructured":"Scalzulli E, Molica M, Alunni Fegatelli D, Colafigli G, Rizzo L, Mancini M, et al. Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice. Ann Hematol. 2019;98:1919\u201325.","journal-title":"Ann Hematol"},{"key":"3347_CR15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/leu.2015.283","volume":"30","author":"AM Zeidan","year":"2016","unstructured":"Zeidan AM, Sekeres MA, Garcia-Manero G, Steensma DP, Zell K, Barnard J, et al. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. 2016;30:649\u201357.","journal-title":"Leukemia"},{"key":"3347_CR16","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJMoa061292","volume":"355","author":"A List","year":"2006","unstructured":"List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456\u201365.","journal-title":"N Engl J Med"},{"key":"3347_CR17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.leukres.2013.12.020","volume":"38","author":"JE Goasguen","year":"2014","unstructured":"Goasguen JE, Bennett JM, Bain BJ, Brunning R, Vallespi MT, Tomonaga M, et al. Proposal for refining the definition of dysgranulopoiesis in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. 2014;38:447\u201353.","journal-title":"Leuk Res"},{"key":"3347_CR18","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.3324\/haematol.13405","volume":"93","author":"GJ Mufti","year":"2008","unstructured":"Mufti GJ, Bennett JM, Goasguen J, Bain BJ, Baumann I, Brunning R, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica. 2008;93:1712\u20137.","journal-title":"Haematologica"},{"key":"3347_CR19","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1182\/bloodadvances.2020001482","volume":"4","author":"BJ Ball","year":"2020","unstructured":"Ball BJ, Famulare CA, Stein EM, Tallman MS, Derkach A, Roshal M, et al. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv. 2020;4:2866\u201370.","journal-title":"Blood Adv"},{"key":"3347_CR20","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1038\/s41375-021-01125-4","volume":"35","author":"MA Sekeres","year":"2021","unstructured":"Sekeres MA, Watts J, Radinoff A, Sangerman MA, Cerrano M, Lopez PF, et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS\/CMML or low-blast AML. Leukemia. 2021;35:2119\u201324.","journal-title":"Leukemia"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03347-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03347-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03347-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T14:41:49Z","timestamp":1658760109000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03347-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,4]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["3347"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03347-3","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,4]]},"assertion":[{"value":"10 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y. Miyazaki received grants from Sumitomo-Dainippon, honoraria from Astellas, SynBio, Nippon-Shinyaku, Novartis, Abbvie, Sumitomo-Dainippon, Chugai; K. Ushiki received grants from Astellas Pharma, AbbVie, Apellis, SymBio, Daiichi-Sankyo, Novartis, Janssen, Otsuka, Astellas-Amgen-Biopharma, Takeda, Nippon-Shinyaku, Bristol-Myers-Squibb, Amgen, Alexion, Incyte, Ono, Kyowa-Kirin, Celgene, Sumitomo-Dainippon, Chugai, Pfizer, Mundi, Yakult, MSD, Gilead, and Nippon-Boehringer-Ingelheim, honoraria from Novartis, Bristol-Myers-Squibb, Sanofi, Pfizer, Abbvie, Takeda, Ono, Kyowa-Kirin, Astellas, Alexion, Eisai, MSD, Otsuka, Celgene, Daiichi-Sankyo, Nippon-Shinyaku, PharmaEssentia, Yakult, SymBio, Alexion, Chugai, and participation in Data Safety Monitoring for Takeda; I. Matsumura received grants from ONO PHARMACEUTICAL CO., LTD., Janssen Pharmaceutical K.K., NIPPON SHINYAKU CO.,LTD., Kyowa Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Shionogi & Co., Ltd., TEIJIN PHARMA LIMITED., Boehringer Ingelheim, Sanofi, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., MSD K.K., ASAHI KASEI PHARMA CORPORATION. Astellas Pharma Inc., Takeda Pharmaceutical Company Limited., Japan Blood Products Organization., NIHON PHARMACEUTICAL CO., LTD, DAIICHI SANKYO COMPANY, LIMITED., AbbVie GK, TAIHO PHARMACEUTICAL CO., LTD., Mitsubishi Tanabe Pharma Corporation, Nippon Kayaku Co., Ltd., CSL Behring, Mundipharma K.K., AYUMI Pharmaceutical Corporation, Eli Lilly Japan K.K., Actelion Pharmaceuticals Japan Ltd., Amgen BioPharma K.K., consulting fee from Otsuka Pharmaceutical Co., Ltd., honoraria from Bristol-Myers Squibb (Celgene), Novartis Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Janssen Pharmaceutical K.K., Astellas Pharma Inc., Takeda Pharmaceutical Company Limited., DAIICHI SANKYO COMPANY, LIMITED., AbbVie GK, Amgen BioPharma K.K.; T. Maeda received grants from Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd., Eisai Co., Ltd., Novartis Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Alexion Pharmaceuticals, Inc., honoraria from Nippon Shinyaku Co., Ltd., Bayer Yakuhin, Ltd., Novartis Pharmaceuticals; A. Tomita received grants from Chugai Pharmaceutical, Ono Pharmaceutical, Kyowa Kiri, Taiho Pharmaceutical, and honoraria from Chugai Pharmaceutical, Takeda Pharmaceutical; H. Handa received grants from Nippon shinyaku, honoraria from Nippon Shinyaku; T. Yamiuchi received honoraria from Nippon Shinyaku; M. Ichikawa received consulting fee from Takeda Pharmaceuticals Co. Ltd.; T. Kiguchi received grants from Nippon Shinyaku Co., Ltd, honoraria from Nippon Shinyaku Co., Ltd; H. Kiyoi received grants from Nippon Shinyaku Co.; T. Naoe received support for the present manuscript from Astellas Pharma, Fuji Film, Daiichi Sankyo, honoraria from Sysmex, Bristol Myers Squibb, participation to Data Safety Monitoring for Nippon Shinyaku, Pfizer, Otsuka Pharma; T. Suzuki received grants from Abbie Inc, Kyowa Kirin Co.,Ltd, Nippon Shinyaku, honoraria from AbbVie Inc, Kyowa Kirin Co., Ltd., Nippon Shinyaku Co., Novartis Pharma K.K., Bristol-Myers Squibb, Ltd; S. Iyama received research funding from Sanofi, Alexion Pharmaceuticals, MSD, Otsuka, SynBio Pharmaceuticals, honoraria from Otsuka Pharmaceuticals Factory, Astellas Pharma, Alexion Pharmaceuticals, CSI Behring, Daiichi Sankyo, Meiji Pharma, Novartis, Nippon Shinyaku, Sanofi, SynBio Pharmaceuticals; S. Chiba received grants from Kyowa-Kirin, Chugai, Ono, Astellas, Eisai, Beyer. Other authors declared that there was no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}